Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma

Relin Yang, Michael C. Cheung, Margaret M. Byrne, Xiaoling Jin, Alberto J. Montero, Catherine Jones, Leonidas Koniaris

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The survival benefit of adjuvant chemotherapy alone or chemoradiotherapy in patients with pancreatic cancer who have undergone surgical resection remains unclear. Objective: To identify the additional benefit of adjuvant therapy by retrospectively examining a large population-based registry of patients who underwent definitive surgical resection for pancreatic adenocarcinoma. Design and Setting: The Florida cancer registry and state inpatient and outpatient hospital data records were queried for pancreatic adenocarcinoma diagnosed between 1998 and 2002. Patients: A total of 2877 patients who underwent surgical resection with curative intent for pancreatic adenocarcinoma were identified. Main Outcome Measure: Overall survival time. Results: Overall, 58.7% of patients were older than 65 years. Most patients were white (90.7%), were non-Hispanic (86.7%), and did not consume alcohol abusively (89.2%). Approximately half of the patients (51.9%) did not receive chemotherapy or chemoradiotherapy. Approximately 25.0% of the patients underwent chemoradiotherapy, and 10.0% received chemotherapy alone. Patients were more frequently treated at low-volume centers (57.6%) and nonteaching facilities (72.8%). Multivariate analysis correcting for patient comorbidities demonstrated that postoperative chemoradiotherapy (hazard ratio=0.69, P=.04) and treatment at high-volume centers (hazard ratio=0.85, P

Original languageEnglish (US)
Pages (from-to)49-56
Number of pages8
JournalArchives of Surgery
Volume145
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Adjuvant Chemoradiotherapy
Survival
Chemoradiotherapy
Adenocarcinoma
Registries
Pancreatic Carcinoma
Drug Therapy
Hospital Records
Adjuvant Chemotherapy
Pancreatic Neoplasms
Comorbidity
Inpatients
Outpatients
Multivariate Analysis

ASJC Scopus subject areas

  • Surgery

Cite this

Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma. / Yang, Relin; Cheung, Michael C.; Byrne, Margaret M.; Jin, Xiaoling; Montero, Alberto J.; Jones, Catherine; Koniaris, Leonidas.

In: Archives of Surgery, Vol. 145, No. 1, 01.2010, p. 49-56.

Research output: Contribution to journalArticle

Yang, Relin ; Cheung, Michael C. ; Byrne, Margaret M. ; Jin, Xiaoling ; Montero, Alberto J. ; Jones, Catherine ; Koniaris, Leonidas. / Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma. In: Archives of Surgery. 2010 ; Vol. 145, No. 1. pp. 49-56.
@article{cd391b04c7274c40a940607336f8e7a7,
title = "Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma",
abstract = "Background: The survival benefit of adjuvant chemotherapy alone or chemoradiotherapy in patients with pancreatic cancer who have undergone surgical resection remains unclear. Objective: To identify the additional benefit of adjuvant therapy by retrospectively examining a large population-based registry of patients who underwent definitive surgical resection for pancreatic adenocarcinoma. Design and Setting: The Florida cancer registry and state inpatient and outpatient hospital data records were queried for pancreatic adenocarcinoma diagnosed between 1998 and 2002. Patients: A total of 2877 patients who underwent surgical resection with curative intent for pancreatic adenocarcinoma were identified. Main Outcome Measure: Overall survival time. Results: Overall, 58.7{\%} of patients were older than 65 years. Most patients were white (90.7{\%}), were non-Hispanic (86.7{\%}), and did not consume alcohol abusively (89.2{\%}). Approximately half of the patients (51.9{\%}) did not receive chemotherapy or chemoradiotherapy. Approximately 25.0{\%} of the patients underwent chemoradiotherapy, and 10.0{\%} received chemotherapy alone. Patients were more frequently treated at low-volume centers (57.6{\%}) and nonteaching facilities (72.8{\%}). Multivariate analysis correcting for patient comorbidities demonstrated that postoperative chemoradiotherapy (hazard ratio=0.69, P=.04) and treatment at high-volume centers (hazard ratio=0.85, P",
author = "Relin Yang and Cheung, {Michael C.} and Byrne, {Margaret M.} and Xiaoling Jin and Montero, {Alberto J.} and Catherine Jones and Leonidas Koniaris",
year = "2010",
month = "1",
doi = "10.1001/archsurg.2009.244",
language = "English (US)",
volume = "145",
pages = "49--56",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma

AU - Yang, Relin

AU - Cheung, Michael C.

AU - Byrne, Margaret M.

AU - Jin, Xiaoling

AU - Montero, Alberto J.

AU - Jones, Catherine

AU - Koniaris, Leonidas

PY - 2010/1

Y1 - 2010/1

N2 - Background: The survival benefit of adjuvant chemotherapy alone or chemoradiotherapy in patients with pancreatic cancer who have undergone surgical resection remains unclear. Objective: To identify the additional benefit of adjuvant therapy by retrospectively examining a large population-based registry of patients who underwent definitive surgical resection for pancreatic adenocarcinoma. Design and Setting: The Florida cancer registry and state inpatient and outpatient hospital data records were queried for pancreatic adenocarcinoma diagnosed between 1998 and 2002. Patients: A total of 2877 patients who underwent surgical resection with curative intent for pancreatic adenocarcinoma were identified. Main Outcome Measure: Overall survival time. Results: Overall, 58.7% of patients were older than 65 years. Most patients were white (90.7%), were non-Hispanic (86.7%), and did not consume alcohol abusively (89.2%). Approximately half of the patients (51.9%) did not receive chemotherapy or chemoradiotherapy. Approximately 25.0% of the patients underwent chemoradiotherapy, and 10.0% received chemotherapy alone. Patients were more frequently treated at low-volume centers (57.6%) and nonteaching facilities (72.8%). Multivariate analysis correcting for patient comorbidities demonstrated that postoperative chemoradiotherapy (hazard ratio=0.69, P=.04) and treatment at high-volume centers (hazard ratio=0.85, P

AB - Background: The survival benefit of adjuvant chemotherapy alone or chemoradiotherapy in patients with pancreatic cancer who have undergone surgical resection remains unclear. Objective: To identify the additional benefit of adjuvant therapy by retrospectively examining a large population-based registry of patients who underwent definitive surgical resection for pancreatic adenocarcinoma. Design and Setting: The Florida cancer registry and state inpatient and outpatient hospital data records were queried for pancreatic adenocarcinoma diagnosed between 1998 and 2002. Patients: A total of 2877 patients who underwent surgical resection with curative intent for pancreatic adenocarcinoma were identified. Main Outcome Measure: Overall survival time. Results: Overall, 58.7% of patients were older than 65 years. Most patients were white (90.7%), were non-Hispanic (86.7%), and did not consume alcohol abusively (89.2%). Approximately half of the patients (51.9%) did not receive chemotherapy or chemoradiotherapy. Approximately 25.0% of the patients underwent chemoradiotherapy, and 10.0% received chemotherapy alone. Patients were more frequently treated at low-volume centers (57.6%) and nonteaching facilities (72.8%). Multivariate analysis correcting for patient comorbidities demonstrated that postoperative chemoradiotherapy (hazard ratio=0.69, P=.04) and treatment at high-volume centers (hazard ratio=0.85, P

UR - http://www.scopus.com/inward/record.url?scp=74549216583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549216583&partnerID=8YFLogxK

U2 - 10.1001/archsurg.2009.244

DO - 10.1001/archsurg.2009.244

M3 - Article

C2 - 20083754

AN - SCOPUS:74549216583

VL - 145

SP - 49

EP - 56

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 1

ER -